Clinical TrialJun 8, 2026, 05:01 PM
Ascendis Pharma to Present New Data at ENDO 2026
AI Summary
Ascendis Pharma A/S announced it will share the latest data from its Endocrinology Rare Disease programs at ENDO 2026, the annual meeting of the Endocrine Society. The presentations will include two oral presentations and three posters covering hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The company aims to showcase the long-term safety and efficacy of TransCon PTH and the long-term benefits of TransCon CNP alone and in combination with TransCon hGH.
Key Highlights
- Ascendis Pharma to present data from three rare endocrine disease programs at ENDO 2026.
- Two oral presentations and three posters will be shared from June 13-16, 2026.
- Oral presentation on final Phase 3 PaTHway trial results for hypoparathyroidism.
- Oral presentation on 52-week Phase 2 COACH trial results for achondroplasia.
- Poster on 156-week PaTHway trial results for hypoparathyroidism.
- Poster on 2-year follow-up data for Lonapegsomatropin in pediatric growth hormone deficiency.
Price Impact
More from ASND